Breaking Finance News

Zacks Investment Research covered Safeguard Scientifics, Inc (NYSE:SFE), hiking its price target to $15.00 today

Safeguard Scientifics, Inc (NYSE:SFE) had its price target upped to $15.00 by Zacks Investment Research in a report issued 10/12/2016. The increased target suggests a potential upside of 0.15% based on the company's last stock close price.

Just yesterday Safeguard Scientifics, Inc (NYSE:SFE) traded -0.23% lower at $13.09. Safeguard Scientifics, Inc’s 50-day moving average is $13.34 and its 200-day moving average is $13.32. The last stock close price is down -2.77% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 21,727 shares of the stock were exchanged, down from an average trading volume of 40,429

See Chart Below

Safeguard Scientifics, Inc (NYSE:SFE)

Safeguard Scientifics, Inc has a 52 week low of $11.40 and a 52 week high of $18.07 The company’s market cap is currently $0.

General Company Details For Safeguard Scientifics, Inc (NYSE:SFE)

Safeguard Scientifics, Inc. provides capital, as well as strategic, operational and management resources to growth-stage businesses. The Company participates in early- and growth-stage financings. The Company operates through two segments: Healthcare and Technology. The Healthcare segment's companies focuses principally on medical technology (MedTech), including diagnostics and devices, and healthcare technology (HealthTech). The Technology segment's companies focuses principally on digital media, financial technology (FinTech), and enterprise software, including mobile technology, cloud, Internet of Things (IoT) and big data. It holds interests in approximately 30 non-consolidated partner companies, which are included in the Healthcare and Technology segments. The Company provides management and operational support, as well as ongoing planning and development assessment. It provides mentoring, advice and guidance to develop partner company management.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *